Experiences with cytoreduction surgery plus hyperthermic intraperitoneal chemotherapy in Taiwan

Mao Chih Hsieh, Chang Yun Lu, Wei Wen Chang, Szu Yuan Wu, Ping Kun Hsiao, Tse Jia Liu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Our hospital was the first institution to offer cytoreduction surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) in Taiwan. Therefore, we report our experience and outcomes among patients who underwent HIPEC. Since 2002, 164 eligible patients underwent HIPEC, and we excluded cases of laparoscopic or prophylactic HIPEC. The cases were categorized according to whether they were treated before 2012 (Period 1: 80 cases) or after 2012 (Period 2: 84 cases). The rates of surgical morbidity were 46.3% during Period 1 and 20.2% during Period 2 (P < .01), and the rates of severe complications were 25% during Period 1 and 9.5% during Period 2 (P < .01). The 5-year overall survival rate was 35.8%, with rates of 13.4% for gastric cancer, 27.3% for colon cancer, 70.0% for appendiceal cancer, and 52.4% for ovarian cancer (median follow-up: 34 months). The survival rate was 42.1% when we achieved a cytoreduction score of 0/1, compared with 21.1% in the group with a cytoreduction score of 2/3 (P < .01). Severe complications were associated with a 5-year survival rate of 23.4%, compared with 37.9% among cases without severe complications (P = .01). Complete cytoreduction was achieved in 78.6% of the patients if they underwent their first surgery at our hospital. We have become an experienced hospital for CRS plus HIPEC. Although our complication rate for CRS plus HIPEC was high, it was within the acceptable range. Long-term survival was achieved in a few cases.

Original languageEnglish
Article numbere7306
JournalMedicine (United States)
Volume96
Issue number26
DOIs
Publication statusPublished - Jun 1 2017

Fingerprint

Taiwan
Drug Therapy
Survival Rate
Colonic Neoplasms
Appendiceal Neoplasms
Ovarian Neoplasms
Stomach Neoplasms
Morbidity
Survival

Keywords

  • completeness of cytoreduction score
  • cytoreduction surgery
  • early postoperative intraperitoneal chemotherapy (EPIC)
  • hyperthermic intraperitoneal chemotherapy (HIPEC)
  • peritoneal cancer index (PCI)
  • peritoneal carcinomatosis
  • peritonectomy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Experiences with cytoreduction surgery plus hyperthermic intraperitoneal chemotherapy in Taiwan. / Hsieh, Mao Chih; Lu, Chang Yun; Chang, Wei Wen; Wu, Szu Yuan; Hsiao, Ping Kun; Liu, Tse Jia.

In: Medicine (United States), Vol. 96, No. 26, e7306, 01.06.2017.

Research output: Contribution to journalArticle

Hsieh, Mao Chih ; Lu, Chang Yun ; Chang, Wei Wen ; Wu, Szu Yuan ; Hsiao, Ping Kun ; Liu, Tse Jia. / Experiences with cytoreduction surgery plus hyperthermic intraperitoneal chemotherapy in Taiwan. In: Medicine (United States). 2017 ; Vol. 96, No. 26.
@article{68b89dab1b6c49169fa41495238a2b9f,
title = "Experiences with cytoreduction surgery plus hyperthermic intraperitoneal chemotherapy in Taiwan",
abstract = "Our hospital was the first institution to offer cytoreduction surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) in Taiwan. Therefore, we report our experience and outcomes among patients who underwent HIPEC. Since 2002, 164 eligible patients underwent HIPEC, and we excluded cases of laparoscopic or prophylactic HIPEC. The cases were categorized according to whether they were treated before 2012 (Period 1: 80 cases) or after 2012 (Period 2: 84 cases). The rates of surgical morbidity were 46.3{\%} during Period 1 and 20.2{\%} during Period 2 (P < .01), and the rates of severe complications were 25{\%} during Period 1 and 9.5{\%} during Period 2 (P < .01). The 5-year overall survival rate was 35.8{\%}, with rates of 13.4{\%} for gastric cancer, 27.3{\%} for colon cancer, 70.0{\%} for appendiceal cancer, and 52.4{\%} for ovarian cancer (median follow-up: 34 months). The survival rate was 42.1{\%} when we achieved a cytoreduction score of 0/1, compared with 21.1{\%} in the group with a cytoreduction score of 2/3 (P < .01). Severe complications were associated with a 5-year survival rate of 23.4{\%}, compared with 37.9{\%} among cases without severe complications (P = .01). Complete cytoreduction was achieved in 78.6{\%} of the patients if they underwent their first surgery at our hospital. We have become an experienced hospital for CRS plus HIPEC. Although our complication rate for CRS plus HIPEC was high, it was within the acceptable range. Long-term survival was achieved in a few cases.",
keywords = "completeness of cytoreduction score, cytoreduction surgery, early postoperative intraperitoneal chemotherapy (EPIC), hyperthermic intraperitoneal chemotherapy (HIPEC), peritoneal cancer index (PCI), peritoneal carcinomatosis, peritonectomy",
author = "Hsieh, {Mao Chih} and Lu, {Chang Yun} and Chang, {Wei Wen} and Wu, {Szu Yuan} and Hsiao, {Ping Kun} and Liu, {Tse Jia}",
year = "2017",
month = "6",
day = "1",
doi = "10.1097/MD.0000000000007306",
language = "English",
volume = "96",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "26",

}

TY - JOUR

T1 - Experiences with cytoreduction surgery plus hyperthermic intraperitoneal chemotherapy in Taiwan

AU - Hsieh, Mao Chih

AU - Lu, Chang Yun

AU - Chang, Wei Wen

AU - Wu, Szu Yuan

AU - Hsiao, Ping Kun

AU - Liu, Tse Jia

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Our hospital was the first institution to offer cytoreduction surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) in Taiwan. Therefore, we report our experience and outcomes among patients who underwent HIPEC. Since 2002, 164 eligible patients underwent HIPEC, and we excluded cases of laparoscopic or prophylactic HIPEC. The cases were categorized according to whether they were treated before 2012 (Period 1: 80 cases) or after 2012 (Period 2: 84 cases). The rates of surgical morbidity were 46.3% during Period 1 and 20.2% during Period 2 (P < .01), and the rates of severe complications were 25% during Period 1 and 9.5% during Period 2 (P < .01). The 5-year overall survival rate was 35.8%, with rates of 13.4% for gastric cancer, 27.3% for colon cancer, 70.0% for appendiceal cancer, and 52.4% for ovarian cancer (median follow-up: 34 months). The survival rate was 42.1% when we achieved a cytoreduction score of 0/1, compared with 21.1% in the group with a cytoreduction score of 2/3 (P < .01). Severe complications were associated with a 5-year survival rate of 23.4%, compared with 37.9% among cases without severe complications (P = .01). Complete cytoreduction was achieved in 78.6% of the patients if they underwent their first surgery at our hospital. We have become an experienced hospital for CRS plus HIPEC. Although our complication rate for CRS plus HIPEC was high, it was within the acceptable range. Long-term survival was achieved in a few cases.

AB - Our hospital was the first institution to offer cytoreduction surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) in Taiwan. Therefore, we report our experience and outcomes among patients who underwent HIPEC. Since 2002, 164 eligible patients underwent HIPEC, and we excluded cases of laparoscopic or prophylactic HIPEC. The cases were categorized according to whether they were treated before 2012 (Period 1: 80 cases) or after 2012 (Period 2: 84 cases). The rates of surgical morbidity were 46.3% during Period 1 and 20.2% during Period 2 (P < .01), and the rates of severe complications were 25% during Period 1 and 9.5% during Period 2 (P < .01). The 5-year overall survival rate was 35.8%, with rates of 13.4% for gastric cancer, 27.3% for colon cancer, 70.0% for appendiceal cancer, and 52.4% for ovarian cancer (median follow-up: 34 months). The survival rate was 42.1% when we achieved a cytoreduction score of 0/1, compared with 21.1% in the group with a cytoreduction score of 2/3 (P < .01). Severe complications were associated with a 5-year survival rate of 23.4%, compared with 37.9% among cases without severe complications (P = .01). Complete cytoreduction was achieved in 78.6% of the patients if they underwent their first surgery at our hospital. We have become an experienced hospital for CRS plus HIPEC. Although our complication rate for CRS plus HIPEC was high, it was within the acceptable range. Long-term survival was achieved in a few cases.

KW - completeness of cytoreduction score

KW - cytoreduction surgery

KW - early postoperative intraperitoneal chemotherapy (EPIC)

KW - hyperthermic intraperitoneal chemotherapy (HIPEC)

KW - peritoneal cancer index (PCI)

KW - peritoneal carcinomatosis

KW - peritonectomy

UR - http://www.scopus.com/inward/record.url?scp=85021711727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021711727&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000007306

DO - 10.1097/MD.0000000000007306

M3 - Article

C2 - 28658135

AN - SCOPUS:85021711727

VL - 96

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 26

M1 - e7306

ER -